Welcome to our dedicated page for CervoMed news (Ticker: CRVO), a resource for investors and traders seeking the latest updates and insights on CervoMed stock.
CervoMed Inc. (CRVO) is a clinical-stage biotechnology company pioneering treatments for neurodegenerative disorders, including dementia with Lewy bodies (DLB). This page serves as the definitive source for official company announcements, research breakthroughs, and clinical development milestones.
Investors and researchers will find timely updates on CervoMed's lead drug candidate neflamapimod, a p38MAPK inhibitor targeting synaptic dysfunction. The curated news collection includes press releases on clinical trial progress, regulatory filings, scientific presentations, and strategic partnerships.
Key updates cover Phase 2b trial developments, biomarker validation studies, and expert analyses of neurodegenerative disease mechanisms. All content is sourced directly from CervoMed's communications to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to CervoMed's latest advancements in neurotherapeutics. Regularly updated to reflect new developments, this resource supports informed decision-making for stakeholders tracking innovative neurological treatments.
CervoMed (NASDAQ: CRVO) has announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder, who will also continue his role as General Counsel and Corporate Secretary, will succeed William Tanner. Tanner will remain with the company as a consultant. CEO John Alam expressed confidence in Elder's expertise in biopharmaceutical and financial operations during this critical phase. The company's RewinD-LB Phase 2b clinical trial is set to complete enrollment in Q2 2024, with efficacy results expected in Q4 2024. Elder's financial background includes roles at Diffusion Pharmaceuticals and Dechert LLP. He holds degrees from the University of Pennsylvania, Villanova University, and Tufts University.
CervoMed, a clinical-stage company developing treatments for age-related neurological disorders, reported its Q1 2024 financial results. The company is on track to complete enrollment for its RewinD-LB Phase 2b trial evaluating neflamapimod in DLB patients by 2Q 2024, with topline data expected in 4Q 2024.
CervoMed completed a private placement of up to $149.4 million in early 2Q 2024, with $50 million received upfront. Cash and cash equivalents as of March 31, 2024, were $6.4 million, excluding the private placement proceeds.
Grant revenue increased to $2.3 million for Q1 2024, while R&D expenses rose to $2.8 million due to the RewinD-LB trial. G&A expenses increased to $2.1 million due to higher operational costs following a reverse merger in August 2023. The company reported an operating loss of $2.6 million but net income of $2.5 million for Q1 2024.
FAQ
What is the current stock price of CervoMed (CRVO)?
What is the market cap of CervoMed (CRVO)?
